GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Physiomics PLC (LSE:PYC) » Definitions » Debt-to-Revenue

Physiomics (LSE:PYC) Debt-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Physiomics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Physiomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.00 Mil. Physiomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.00 Mil. Physiomics's annualized Revenue for the quarter that ended in Dec. 2023 was £0.75 Mil. Physiomics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.


Physiomics Debt-to-Revenue Historical Data

The historical data trend for Physiomics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Physiomics Debt-to-Revenue Chart

Physiomics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Physiomics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Physiomics's Debt-to-Revenue

For the Biotechnology subindustry, Physiomics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Physiomics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Physiomics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Physiomics's Debt-to-Revenue falls into.



Physiomics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Physiomics's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Physiomics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


Physiomics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Physiomics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Physiomics (LSE:PYC) Business Description

Traded in Other Exchanges
Address
140 Eastern Avenue, Bee House, Milton Park, Oxfordshire, GBR, OX14 4SB
Physiomics PLC is a United Kingdom-based firm providing services to pharmaceutical companies through outsourced systems and computational biology. The company is mainly engaged in the development of models to streamline the drug discovery and development process. It focuses to transform oncology drug development. The company operates in the UK, European Union Switzerland and USA.

Physiomics (LSE:PYC) Headlines

No Headlines